Glenmark Pharma Returns to Profit in Q4 FY25, Posts Rs 1,389 Crore Annual PAT, Declares Final Dividend

Glenmark Pharmaceuticals Limited, a research-led global pharmaceutical company, reported a strong financial turnaround in the fourth quarter of FY25, swinging to a net profit of Rs 4.7 crore from a loss of Rs 1,218 crore in the same period last year. For the full year, the company posted a consolidated adjusted profit after tax (PAT) of Rs 1,389.4 crore and revenues of Rs 13,321.7 crore, marking a 12.8% year-on-year increase.

Glenmark Pharma Q4 Results 2025: Net Profit, Revenue and Final Dividend

Glenmark's consolidated revenue for the quarter ended 31 March 2025 stood at Rs 3,256 crore, up 6.3% from Rs 3,063 crore in Q4 FY24. The company recorded EBITDA of Rs 561 crore, an 11.2% increase, with margins improving to 17.2%. Adjusted PAT came in at Rs 346.6 crore for the quarter, translating into an adjusted PAT margin of 10.6%.

Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said while declaring earnings, "Our performance reflects the underlying resilience of our business, the strength of our diversified portfolio, and the focused execution of our strategic priorities."

Glenmark Pharma Final Dividend Announced: Check Payout, Recording Date

The Board of Directors of the pharmaceutical company has declared a dividend of Rs 2.5 per equity share with a face value Rs 2 each, subject to shareholder approval at the upcoming Annual General Meeting (AGM). The total proposed dividend payout stands at Rs 70.5 crore, including Rs 8.6 crore to be disbursed to retail investors. Payouts will be made within 30 days following the AGM.

Glenmark Pharma Q4 Results 2025 Full-Year FY25 Performance

Over the course of FY25, Glenmark achieved significant operational momentum. Revenue rose to Rs 13,321.7 crore, EBITDA nearly doubled to Rs 2,351 crore, and adjusted PAT reached Rs 1,389.4 crore, up from Rs 961 crore in the previous year. EBITDA margin for the year improved to 17.6%, while the adjusted PAT margin stood at 10.4%.

Glenmark Pharma Geographical Revenue:

Glenmark Pharma Sales in India: Full-year sales from the India formulation business increased 31.9% to Rs 4,484.5 crore. Q4 revenues were Rs 943 crore, up marginally by 0.4%.

Europe: Revenues surged 17.6% to Rs 2,846.3 crore for FY25, with Q4 growth of 20% to Rs 733.5 crore.

Rest of the World (RoW): Revenue grew by 1.7% to Rs 2,813.8 crore for the full year, and 5% YoY in Q4 to Rs 789.8 crore.

North America: Revenue declined 5.4% in Q4 to Rs 714.6 crore, impacted by pricing pressure in the generics segment.

"The Europe business has shown strong growth, and our branded businesses have delivered sustained results, supported by market expansion and a sharp therapeutic focus. As we move into FY26, we remain committed to building this momentum as we strengthen our global footprint," Glenmark Pharma MD announced.

Glenmark Pharma Share Price Today

Glenmark Pharmaceuticals Ltd closed at Rs 1,421.90 on May 23, marking a decline of Rs 9.50 or 0.66% as investors remained watchful ahead of the company's Q4 earnings release. The stock opened at Rs 1,432.80, reached a high of Rs 1,439.00, and touched a low of Rs 1,409.20 during the trading session.